New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders
Synapse · 2024-07 · 78 (4)
DOI: 10.1002/syn.22301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Synapse, online erschienen am 31.05.2024. Verfasst von Daniel Juarez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemical Sciences, Benemeritus Autonomous University of Puebla, Puebla, Puebla, Mexico. Hauptthemen laut MEDLINE: Phenylbutyrates, Nervous System Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: PAPITT-UNAM, Vicerrectoría de Investigación y Estudios de Posgrado, Benemérita Universidad Autónoma de Puebla.
Abstract (Originalsprache)
Neurological disorders (NDs) are diseases of the central and peripheral nervous systems that affect more than one billion people worldwide. The risk of developing an ND increases with age due to the vulnerability of the different organs and systems to genetic, environmental, and social changes that consequently cause motor and cognitive deficits that disable the person from their daily activities and individual and social productivity. Intrinsic factors (genetic factors, age, gender) and extrinsic factors (addictions, infections, or lifestyle) favor the persistence of systemic inflammatory processes that contribute to the evolution of NDs. Neuroinflammation is recognized as a common etiopathogenic factor of ND. The study of new pharmacological options for the treatment of ND should focus on improving the characteristic symptoms and attacking specific molecular targets that allow the delay of damage processes such as neuroinflammation, oxidative stress, cellular metabolic dysfunction, and deregulation of transcriptional processes. In this review, we describe the possible role of sodium phenylbutyrate (NaPB) in the pathogenesis of Alzheimer's disease, hepatic encephalopathy, aging, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis; in addition, we describe the mechanism of action of NaPB and its beneficial effects that have been shown in various in vivo and in vitro studies to delay the evolution of any ND.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemical Sciences, Benemeritus Autonomous University of Puebla, Puebla, Puebla, Mexico.
- Department of Reproductive Biology and Toxicology, Institute of Sciences. Benemeritus Autonomous University of Puebla, Puebla, Puebla, Mexico.
- Institute of Physiology, Benemeritus Autonomous University of Puebla, Puebla, Puebla, Mexico.
- Faculty of Medicine, Department of Biochemistry, National Autonomous University of Mexico, Mexico City, Mexico.
ORCID-Profile: Daniel Juarez, Gonzalo Flores, Alfonso Diaz
Förderung
- PAPITT-UNAM
- Vicerrectoría de Investigación y Estudios de Posgrado, Benemérita Universidad Autónoma de Puebla
Zitieren
APA
Juarez, D., Handal-Silva, A., Morán-Perales, J. L., Torres-Cifuentes, D. M., Flores, G., Treviño, S., Moreno-Rodriguez, A., Guevara, J., & Diaz, A. (2024). New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders. Synapse, 78(4). https://doi.org/10.1002/syn.22301
Vancouver
Juarez D, Handal-Silva A, Morán-Perales JL, Torres-Cifuentes DM, Flores G, Treviño S, et al. New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders. Synapse. 2024;78(4). doi:10.1002/syn.22301
BibTeX
@article{Juarez2024,
author = {Juarez, Daniel and Handal-Silva, Anabella and Morán-Perales, Jose Luis and Torres-Cifuentes, Diana M and Flores, Gonzalo and Treviño, Samuel and Moreno-Rodriguez, Albino and Guevara, Jorge and Diaz, Alfonso},
title = {New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders},
journal = {Synapse},
year = {2024},
volume = {78},
number = {4},
doi = {10.1002/syn.22301}
}
EUVIMED